Mullick Adam,Crooke Rosanne M.,Graham Mark J.,Dobie Kenneth W.,Bell Thomas A.,Lee Richard
申请号：
NZ71019212
公开号：
NZ710192A
申请日:
2012.04.27
申请国别(地区):
NZ
年份:
2017
代理人:
摘要：
Disclosed is the use of a compound targeting ApoCIII in the manufacture of a medicament for increasing HDL levels and/or improving the ratio of TG to HDL in an animal thereby increasing chylomicron clearance in an animal； wherein the compound comprises a modified oligonucleotide comprising or consisting of the sequence of SEQ ID NO: 3 and wherein the compound is capable of inhibiting apolipoprotein C-III. Further disclosed is the use of a compound comprising a modified oligonucleotide targeting ApoCIII comprising or consisting of SEQ ID NO: 3, wherein the modified oligonucleotide comprises: (a) a gap segment consisting of 10 linked deoxynucleosides； (b) a 5’ wing segment consisting of 5 linked nucleosides； (c) a 3’ wing segment consisting 5 linked nucleosides； wherein the gap segment is positioned immediately adjacent to and between the 5’ wing segment and the 3’ wing segment, wherein each nucleoside of each wing segment comprises a 2’-O-methoxyethyl sugar, wherein each cytosine is a 5-methylcytosine, and wherein each internucleoside linkage is a phosphorothioate linkage； and wherein the modified oligonucleotide is capable of inhibiting the expression of apolipoprotein C-III； in the manufacture of a medicament for increasing HDL levels and/or improving the ratio of TG to HDL in an animal thereby increasing chylomicron clearance in an animal.
